CORDIS - Forschungsergebnisse der EU
CORDIS

Commercial feasibility of microbial therapy

Ziel

Our body is colonized by complex microbial communities (our microbiome) that are most abundant in the intestinal tract where they contribute significantly to our health and disease. It has been established that aberrations in our microbiome are of particular importance in obesity, type 2 diabetes and metabolic syndrome, rapidly growing diseases with a drug market volume of over 5 B$ per year. We have discovered in the ERC project Microbes Inside that a particular bacterium is able to modify the intestinal microbiome and may be used to develop a new approach to treat these and other metabolic diseases. The Proof of Concept project ACOM aims to confirm the commercial and technological feasibility of this approach, consolidate and expand our IP position, and develop a product development plan. These form the elements of a business plan that is expected to result in establishing a spin out company (ACOM).

Aufforderung zur Vorschlagseinreichung

ERC-2013-PoC
Andere Projekte für diesen Aufruf anzeigen

Gastgebende Einrichtung

WAGENINGEN UNIVERSITY
EU-Beitrag
€ 142 000,00
Adresse
DROEVENDAALSESTEEG 4
6708 PB Wageningen
Niederlande

Auf der Karte ansehen

Region
Oost-Nederland Gelderland Veluwe
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Tom Bessems (Mr.)
Links
Gesamtkosten
Keine Daten

Begünstigte (1)